Dr. Pherson Faces DEA Decree: Another Day in Reg Hell
Published Date: 8/20/2025
Notice
Summary
Kenneth Pherson, D.O., lost his DEA registration because he no longer has permission to handle controlled substances in Florida. He didn’t ask for a hearing after being notified, so the DEA moved forward and officially revoked his registration. This means Dr. Pherson can’t legally prescribe or manage controlled drugs anymore, effective immediately.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
DEA Registration Revoked for Dr. Pherson
DEA Certificate of Registration No. FP0455142 issued to Kenneth Pherson, D.O., is revoked and any pending applications to renew, modify, or obtain registration in Florida are denied. The Order is effective September 19, 2025, after the Agency found his Florida osteopathic medical license suspended on or about August 29, 2024, and he did not request a hearing following the December 2, 2024 Order to Show Cause.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-17589, Leila Kump, M.D.; Decision and Order
2026-17594, Atlantic Treatment Center, LLC; Decision and Order
The DEA has officially shut down Atlantic Treatment Center in Florida because it lost its state license and federal certification to treat substance use disorders. This means the center can no longer operate legally, protecting public health and safety. The center’s DEA registration expired on June 30, 2026, and this decision finalizes the revocation, making it clear no more services can be offered.
2026-17592, Thomas Earley, D.D.S.; Decision and Order
Dr. Thomas Earley from Ohio lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately.
2026-17531, Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
The Drug Enforcement Administration (DEA) issues this temporary order to schedule 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4- yl)-5,6-dichloro-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro brorphine or SR-14968); 5,6-dichloro-1-(1-(4- chlorobenzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro desmethylchlorphine or SR-17018); 3-(3- (1-(1-(4-chlorophenyl)ethyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-1-yl)propanenitrile (commonly known as N-propionitrile chlorphine or cychlorphine); and 8-(1-(4-chlorophenyl)ethyl)-1-phenyl- 1,3,8-triazaspiro[4.5]decan-4-one (commonly known as spirochlorphine or R-6890), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, to schedule I under the Controlled Substances Act. DEA bases this action on a finding that placing 5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N- propionitrile chlorphine, and spirochlorphine in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle these substances.
Previous / Next Documents
Previous: 2025-15866, Andrew Konen, M.D.; Decision and Order
Dr. Andrew Konen from Dallas lost his DEA license because he wrote lots of prescriptions for strong drugs in ways that weren’t legal or safe. He didn’t show up to defend himself, so the government decided to revoke his registration and deny any future applications. This means he can’t legally prescribe controlled substances anymore, starting now.
Next: 2025-15868, Transcontinental Gas Pipe Line Company, LLC; Notice of Request for Extension of Time
Transcontinental Gas Pipe Line Company (Transco) asked for more time to finish its Central Louisiana Abandonment Project offshore Louisiana, pushing the deadline from September 3, 2025, to December 31, 2026. They ran into problems like bad weather and limited vessel availability, which slowed things down. This affects anyone following the project timeline and could delay related plans, but no new costs were mentioned yet.